STOCK TITAN

HCA Healthcare (HCA) 424B Filings

HCA NYSE

Here are the 424B prospectus supplements from HCA Healthcare, Inc. (HCA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow HCA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCA filings page.

Rhea-AI Summary

HCA Healthcare, Inc.'s wholly owned subsidiary HCA Inc. is offering $6.5 billion aggregate principal amount of seven senior-note series. The six fixed-rate series carry coupons of 5.200% to 6.500%; the $300 million floating-rate series pays Compounded SOFR plus 0.750%. Maturities run from November 3, 2028, through November 15, 2056.

HCA Inc. estimates net proceeds of approximately $6.430 billion after underwriting discounts and estimated offering expenses. It intends to use the proceeds for general corporate purposes, which may include redeeming all or part of the $1.200 billion outstanding 4.500% senior notes due 2027 and repaying commercial-paper or senior-credit-facility borrowings. As of September 30, 2026, HCA Healthcare's adjusted capitalization shows total debt of $50.493 billion.

HCA Healthcare guarantees the notes on a senior unsecured basis. The notes rank equally with HCA Inc.'s senior indebtedness, are structurally subordinated to subsidiary liabilities, and are effectively subordinated to secured debt to the value of its collateral. Fixed-rate notes may be redeemed under the stated terms; floating-rate notes cannot be redeemed before maturity. After a Change of Control Triggering Event, holders may require repurchase at 101% of face amount plus accrued and unpaid interest.

Rhea-AI Summary

HCA Healthcare, Inc. (HCA) subsidiary HCA Inc. is offering multiple series of senior notes, including fixed-rate and floating-rate notes. HCA Healthcare, Inc. will guarantee the notes on a senior unsecured basis. The notes rank equally with HCA Inc.’s senior debt, are structurally subordinated to liabilities of its subsidiaries, and effectively subordinated to secured debt to the extent of collateral value. On an as-adjusted basis after the offering and use of proceeds, the notes would be structurally subordinated to $1.005 billion of secured subsidiary debt.

HCA Inc. intends to use net proceeds for general corporate purposes, which may include redeeming all or part of its $1.200 billion of 4.500% senior notes due 2027, repaying commercial paper borrowings, or repaying borrowings under its senior unsecured credit facility. Any redemption would require a separate notice. Fixed-rate notes may be redeemed at the stated redemption prices; floating-rate notes cannot be redeemed before maturity. After a Change of Control Triggering Event, holders may require repurchase at 101% of face amount plus accrued and unpaid interest. As of September 30, 2026, HCA Healthcare, Inc. reported $50.493 billion of total debt, including $43.750 billion of senior notes and $5.727 billion of commercial paper.

Rhea-AI Summary

HCA Inc. is offering $3,000,000,000 aggregate principal amount of senior notes: $1,000,000,000 4.700% notes due May 15, 2031, $750,000,000 5.000% notes due May 15, 2033, and $1,250,000,000 5.300% notes due May 15, 2036. Interest on each series is payable semi‑annually on May 15 and November 15, beginning November 15, 2026.

HCA intends to use net proceeds (estimated at $2.975 billion) to redeem in full its outstanding $1.500 billion 5.250% notes due June 2026 and $1.000 billion 5.375% notes due September 2026 and for general corporate purposes, which may include repayment of commercial paper. The notes are senior unsecured obligations of HCA Inc. and are guaranteed on a senior unsecured basis by HCA Healthcare, Inc.

Rhea-AI Summary

HCA Inc. is offering multiple series of senior notes, each to be fully and unconditionally guaranteed on a senior unsecured basis by parent HCA Healthcare, Inc. The prospectus supplement states interest will be paid semi‑annually and the notes may be redeemed optionally; a Change of Control Triggering Event would permit holders to require repurchase at 101% plus accrued interest. Net proceeds are intended for general corporate purposes and may be used to repay commercial paper and to redeem some or all of the $1.500 billion 5.250% notes due June 2026 and the $1.000 billion 5.375% notes due September 2026. The document also discloses first quarter 2026 operating results: revenues of $19.109 billion, net income attributable to HCA Healthcare, Inc. of $1.620 billion and Adjusted EBITDA of $3.802 billion.